A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation
Latest Information Update: 30 May 2025
At a glance
- Drugs ABN 401 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abion
Most Recent Events
- 22 May 2025 Planned number of patients changed from 40 to 178.
- 22 May 2025 Status changed from active, no longer recruiting to recruiting.
- 22 May 2025 Planned End Date changed from 1 Aug 2025 to 1 Feb 2029.